Aeglea BioTherapeutics Investor Presentation Deck

Cash and anticipated milestones CASH RUNWAY $ 236.7M as of 6/30/2023 expected to fund pipeline into 2026 through multiple key value creation events Note: ¹As of October 23, 2023 SPYRE CATALYSTS¹ SPY001 (a437) SPY002 (TL1A) SPY003 (IL-23) COMBINATIONS EXTERNAL EVENTS 2024 EXPECTED 1H - IND/CTN 2H - PHASE 1 INTERIM DATA 2H - IND/CTN 1H PRA023 SSC-ILD P2 2H TEV-48574 P2b 2H - DUET UC/CD P2b 2025 EXPECTED PHASE 1 FULL DATA PHASE 2 INITIATION PHASE 1 INTERIM DATA IND/CTN PHASE 2 INITIATION MORF057 P2b 35

View entire presentation